The role of radical surgery in advanced epithelial ovarian cancer

ISRCTN	ISRCTN62526210
DOI	https://doi.org/10.1186/ISRCTN62526210
Secondary identifying numbers	OV3006

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study design	Randomised controlled trial
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Hospital
Study type	Treatment
Participant information sheet	Not available in web format, please use the contact details below to request a patient information sheet
Scientific title	The role of radical surgery in advanced epithelial ovarian cancer
Study objectives	Not provided at time of registration
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Ovarian cancer
Intervention	Patients are randomised to one of two treatment arms: 1. Arm A: High activity platinum based chemotherapy. The recommended chemotherapy regimen is cyclophosphamide and cisplatin given for a maximum of eight cycles. 2. Arm B: Radical debulking surgery followed by chemotherapy as described above.
Intervention type	Mixed
Primary outcome measure	Not provided at time of registration
Secondary outcome measures	Not provided at time of registration
Overall study start date	01/01/1990
Completion date	31/12/1995

Participant type(s)	Patient
Age group	Not Specified
Sex	Female
Target number of participants	Not provided at time of registration
Key inclusion criteria	1. Histologically confirmed epithelial ovarian cancer 2. Macroscopic residual disease unlikely in surgeon's opinion to be completely debulked without bowel resection or other procedures 3. No attempt to radically debulk 4. No prior chemotherapy or radiotherapy 5. No previous or concurrent malignancy other than non melanomatous skin cancer 6. No haematological or biochemical contra-indication to platinum chemotherapy 7. No contraindication to second laparotomy 8. Available to commence chemotherapy or undergo further surgery within 6 weeks of diagnostic laparotomy
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	01/01/1990
Date of final enrolment	31/12/1995

MRC Clinical Trials Unit

London
NW1 2DA
United Kingdom

Cancer Research UK (CRUK) (UK)
Charity

PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom

Charity

Cancer Research UK
Private sector organisation / Other non-profit organizations

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

30/10/2019: No publications found, all search options exhausted, study status unverified.